### WHO Guidelines: Grading evidence and developing evidencebased guidelines

### Suzanne Hill

### **Training Course in Reproductive Health/Sexual Health Research**

February 2008







### What is a guideline?

### Medical guideline/clinical guideline, clinical practice guideline

"Systematically developed statements to assist practitioner and patient decisions about appropriate healthcare for specific clinical circumstances"

Field & Lohr, 1992



### **Other terms**


 Clinical protocol/critical pathway/integrated care pathway

"Management recommendation based on a programmed description of the policy, containing well-defined choices regarding the policy to be followed, based on agreements between the disciplines involved."

Altena et al 1994



## Why are they important?







### We know what to do...

- Prescribe beta-blockers for patients after myocardial infarction
- Wash hands between patients
- Not prescribe antibiotics for viral upper respiratory tract infections
- Stop smoking....





# So to improve clinical decision making and quality of care...

### Clinical guidelines with :

- 7 Concrete aims and objective
- Sufficient evidence to support most of the recommendations
- Clear structure and attractive layout
- Clear and specific recommendations
- Taking account of norms and values
- Applicable in different settings



### So what is evidence?

- Stanford Encyclopedia of Philosophy
- The concept of evidence is central to both epistemology and the philosophy of science. Of course, 'evidence' is hardly a philosopher's term of art: it is not only, or even primarily, philosophers who routinely speak of evidence, but also lawyers and judges, historians and scientists, investigative journalists and reporters, as well as the members of numerous other professions and ordinary folk in the course of everyday life.
- And when we try to define 'evidence' ... we find it very difficult.

-R.G. Collingwood, The Idea of History



### Professional good intentions and plausible theories are insufficient for selecting policies and practices for protecting, promoting and restoring health.

 We will serve the public more responsibly and ethically when research designed to reduce the likelihood that we will be misled by bias and the play of chance has become an expected element of professional and policy making practice, not an optional add-on.

### **Iain Chalmers**



### How do we judge that we are sure that adherence to a recommendation will do more good than harm?



## **Does an intervention work?**

Review: Prophylactic oxytocin for the third stage of labour Comparison: 01 Oxytocin versus no uterotonics (all trials) Outcome: 01 PPH (clinically estimated blood loss > or = 500 ml)

Study	Oxytocin n/N	Control n/N	Relative Risk (Fixed) 95% Cl	Weight (%)	Relative Risk (Fixed) 95% Cl	
De Groot 1996	25/78	55/143		10.2	0.83 [0.57, 1.22]	
Howard 1964	15/470	25/470		6.6	0.60 [0.32, 1.12]	
🗙 llancheran 1990	0/5	0/5		0.0	Not estimable	
Nordstrom 1997	104/513	175/487		47.1	0.56 [0.46, 0.70]	
Pierre 1992	37/488	126/482		33.3	0.29 [0.21, 0.41]	
Poeschmann 1991	7/28	10/24		2.8	0.60 [0.27, 1.33]	
Total (95% CI) Total events: 188 (Ox) Test for heterogeneity Test for overall effect	chi-square=18.10 df	1611 =4 p=0.001 l= =77.9%	•	100.0	0.50 [0.43, 0.59 ]	
			0.1 0.2 0.5 1 2 5 Favours Oxytocin Favours Co	10 ontrol		



### **Does a screening test save lives?**

Review: Screening for breast cancer with mammography Comparison: 01 Screening with mammography versus no screening Outcome: 01 Deaths ascribed to breast cancer, 7 years follow up

Study	Screening n/N	No screening n/N	Relative Risk (Fixed) 95% Cl	Weight (%)	Relative Risk (Fixed) 95% Cl
01 Adequately randomise Canada 1980a	ed trials 38/25214	28/25216		5.4	1.36 [ 0.83, 2.21 ]
Canada 1980b	38/19711	39/19694		7.5	0.97 [0.62, 1.52]
Malmö 1976	63/21088	66/21195	<b>_</b> _	12.7	0.96 [0.68, 1.35]
Subtotal (95% CI) Total events: 139 (Scree Test for heterogeneity cl Test for overall effect z=	ni-square=1.44 df=2		•	25.5	1.05 [0.83, 1.33]
02 Suboptimally randomi Göteborg 1982a	sed trials 6/10821	10/13101		1.7	0.73 [0.26, 2.00]
Göteborg 1982b	21/9903	37/15708		5.5	0.90 [0.53, 1.54]
Kopparberg 1977	71/39051	52/18846	<b>_</b>	13.5	0.66 [0.46, 0.94]
Malmö II 1978	29/9581	33/8212		6.8	0.75 [ 0.46, 1.24 ]
New York 1963	81/31000	124/31000		23.8	0.65 [0.49, 0.86]
Stockholm 1981	53/38525	40/20651		10.0	0.71 [ 0.47, 1.07 ]
Östergötland 1978	53/39034	67/37936		13.1	0.77 [ 0.54, 1.10 ]
Subtotal (95% CI) Total events: 314 (Scree Test for heterogeneity cl Test for overall effect z=	ni-square=1.51 df=6		•	74.5	0.71 [0.81, 0.83]
Total (95% CI) Total events: 453 (Scree Test for heterogeneity cl Test for overall effect z=	hi-square=10.12 df=9		•	100.0	0.80 [0.70, 0.91]
			0.2 0.5 1 2 Favours screening Favours no scree	5 ening	



# What makes children wear a bicycle helmet?

Review: Non-legislative interventions for the promotion of cycle helmet wearing by children Comparison: 01 Non-legislative interventions vs control Outcome: 02 Self-reported helmet ownership

Study	Treatment n/N	Control n/N	Odds Ratio (Random) 95% Cl	Weight (%)	Odds Ratio (Random) 95% Cl
Britt 1998	239/249	51/82		17.3	14.53 [ 6.70, 31.51 ]
Cushman 1991a	15/161	14/173		17.3	1.17 [0.54, 2.50]
Cushman 1991b	12/167	12/172		17.0	1.03 [0.45, 2.37 ]
Farley 1996	11/48	6/47		15.5	2.03 [0.68, 6.04]
Stutts 1990	6/67	7/54		15.1	0.66 [0.21, 2.10]
Towner 1992	26/98	23/81		17.8	0.91 [ 0.47, 1.76 ]
Total (95% CI) Total events: 309 (Treatm Test for heterogeneity ch Test for overall effect z=	hi-square=37.95 df=5 j	609 p=<0.0001 l² =86.8%		100.0	1.69 [0.65, 4.38]
			0.01 0.1 1 10 Favours control Favours treatme	100 ent	



### How would you grade that evidence?

Evidence	Recommendation	Organization
II-2	В	USPSTF
C+	1	ACCP
Strong	Strongly recommended	SIGN



## Recommendation for use of oral anticoagulation in patients with atrial fibrillation and mitral valve disease

Evidence	Recommendation	Organization
II-2	В	USPTSTF
C+	1	ACCP
Strong	Strongly recommended	SIGN



### Problem

- Too many systems
- They only evaluate design
- No consideration of other important factors that influence judgements and recommendations



## Why bother about grading?

- People draw conclusions about
  - Quality of evidence
  - Strength of recommendations
- Systematic explicit approaches help
  - Protect against errors
  - Resolve disagreements
  - Facilitate critical appraisal
  - 7 Communicate information



## What about WHO guidelines?





# Grades of Recommendation Assessment Development and Evaluation



## Definitions

### **Quality of evidence**

the extent to which one can be confident that an estimate of effect or association is correct

Four categories

High ++++

*Further research is very unlikely to change our confidence in the estimate of effect* 

- Moderate +++
   Further research is likely to have an important impact...
  - Low ++

Further research is very likely to have an important impact.....

Very low +
 Any estimate of effect is very uncertain




# The quality of evidence needs to be considered for each important outcome

#### A review or guideline needs a clearly formulated question

- Patients or population
- Intervention
- **7** Comparison
- **7** Outcomes
- The quality of evidence may be different for different outcomes
- Decision makers (and review authors) need to consider the relative importance of outcomes



Hierarchy of outcomes according to their importance to assess the effect of phosphate lowering drugs in patients with renal failure and hyperphosphatemia





## **Study design is important**

- Early systems of grading the quality of evidence focused almost exclusively on study design
- Randomised trials provide, in general, far stronger evidence than observational studies.
  - Randomised trials start out at High
  - Observational studies start out at Low
- However, other factors may decrease or increase the quality of evidence



# Factors that may decrease the quality of evidence

- Study limitations
- Inconsistency of results
- Indirectness of evidence
- Imprecise results
- Reporting bias



# Factors that may increase the quality of evidence

- ▲ Large magnitude of effect
- ▲ A dose response relationship



### **Quality assessment criteria**

Quality of evidence	Study design	Lower if	Higher if
High	Randomised trial	Study quality: -1 Serious	Strong association: +1 Strong, no
Moderate		limitations -2 Very serious	plausible confounders
Low	Observational study	limitations	+2 Very strong, no major threats to
Very low		<ul> <li>-1 Important inconsistency</li> </ul>	validity
		<ul> <li>Directness:</li> <li>-1 Some uncertainty</li> <li>-2 Major uncertainty</li> <li>-1 Sparse or imprecise data</li> <li>-1 High probability of reporting bias</li> </ul>	+1 Evidence of a Dose response gradient



### **Strength of recommendation**

The degree of confidence that the desirable effects of adherence to a recommendation outweigh the undesirable effects.



# Desirable effects

- health benefits
- less burden
- savings

## Undesirable effects

- •harms
- •more burden
- •costs



### **Categories of recommendations**

Although the degree of confidence is a continuum, we suggest using two categories: strong and weak.

- Strong recommendation: the panel is confident that the desirable effects of adherence to a recommendation outweigh the undesirable effects.
- Weak recommendation: the panel concludes that the desirable effects of adherence to a recommendation probably outweigh the undesirable effects, but is not confident.

Recommend ↑↑ ↓↓

> Suggest ↑ ↓



## **Determinants of strength of recommendation**

Factors	Impact on the strength of a recommendation
Balance between desirable and undesirable effects	Larger the difference between the desirable and undesirable effects, more likely a strong recommendation warranted. Narrower the gradient, more likely weak recommendation warranted.
Quality of the evidence	Higher the quality of evidence, more likely a strong recommendation warranted.
Values and preferences	More variability in values and preferences, or more uncertainty in values and preferences, more likely weak recommendation warranted.
Costs (resource use)	Higher the costs of an intervention – that is, the more resources consumed – less likely a strong recommendation warranted.



# Judgements about the strength of a recommendation

- No precise threshold for going from a strong to a weak recommendation
- The presence of important concerns about one or more of these factors make a weak recommendation more likely.
- Panels should consider all of these factors and make the reasons for their judgements explicit.
- Recommendations should specify the perspective that is taken (e.g. individual patient, health system) and which outcomes were considered (including which, if any costs).



### **Implications of a strong recommendation**

- Patients: Most people in your situation would want the recommended course of action and only a small proportion would not
- Clinicians: Most patients should receive the recommended course of action
- Policy makers: The recommendation can be adapted as a policy in most situations



### **Implications of a weak recommendation**

- Patients: The majority of people in your situation would want the recommended course of action, but many would not
- Clinicians: Be prepared to help patients to make a decision that is consistent with their own values
- Policy makers: There is a need for substantial debate and involvement of stakeholders



### Example

- Post partum haemorrhage is the major cause of maternal mortality
- Effective interventions are available active management
- Which ones?
- Is one better than the other?
- Who should use them?



Should active management of the third stage of labour be used by skilled providers for all women to prevent post-partum haemorrhage?



		Qualit	y assessment			Summary of findings						
	No of patients Effect				Effect	i						
No of studie s (Ref)	Desig n	Limitation s	Consistenc y	Directn ess	Other considerati ons	Active manage ment	Standard procedure s	Baseline Risk (95%Cl)	Relative risk (95%Cl)	NNT (95%CI)	Quality	Importanc e
Benefits	:				l							
Maternal	deaths											-
0	-	-	-	-	-	-	-	-	-	-	-	8.5
Admissio	on to inten	sive care unit			-					_		
0	-	-	-	-	-	-	-	-	-	-	-	6.4
Blood los	ss ≥ 500 m	I										
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> 17	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 8.3% (6.3, 10.3) max 17.9% (15.3, 20.5)	0.38 (0.32, 0.46)	min 8 (6.7, 11.2) max 16 (11.7, 24.7)		6.3
Blood los	ss ≥ 1000 r	nl						1	1	1		
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> 17	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 1.5% (0.6-2.4) max 3.2% (2.0-4.4)	0.33 (0.21, 0.51)	min 41 (26.5, 90.1) max 73 (43.3, 225.5)		7.7
Need for	blood tran	sfusion				•		•	•		•	•
5 PW 00 <sup>1</sup> Ad 97 Br 93 Br 88	RCT	minor limitation <sup>3,8</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>7</sup>	none	3229	3248	5.7% (4.1-7.2) <sup>16</sup>	0.34 (0.22, 0.53)	28 (18.7, 59,1) <sup>16</sup>		7.8
Du 90 Hi 98												
											World Orga	l Heal nizatio

		Quality assessment											
No of studie s (Ref)	Desig n	Limitation S	Consistenc y	Directn ess	Other considerati ons								
Benefits	its:												
Materna	Maternal deaths												
0	-	-	-	-	-								
Admissi	on to inten	sive care unit											
0	-	-	-	-	-								
Blood lo	ss ≥ 500 m	I											
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> <sup>17</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none								
Blood lo	ss ≥ 1000 r	nl											
4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> <sup>17</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none								
Need for	blood trar	sfusion											
5 PW 00 <sup>1</sup> Ad 97 Br 93 Br 88	RCT	minor limitation <sup>3,8</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>7</sup>	none								
Du 90 Hi 98													



			gs	nary of findin	Sumn		
				Effect	patients	No of	
c	Importanc e	Quality	NNT (95%Cl)	Relative risk (95%Cl)	Baseline Risk (95%Cl)	Standard procedure s	Active manage ment
	8.5	-	-	-	-	-	-
_	6.4	-	-	-	-	-	-
	6.3		min 8 (6.7, 11.2) max 16 (11.7, 24.7)	0.38 (0.32, 0.46)	min 8.3% (6.3, 10.3) max 17.9% (15.3, 20.5)	3158	3126
	7.7		min 41 (26.5, 90.1) max 73 (43.3, 225.5)	0.33 (0.21, 0.51)	min 1.5% (0.6-2.4) max 3.2% (2.0-4.4)	3158	3126
$\neg$							
	7.8		28 (18.7, 59,1) <sup>16</sup>	0.34 (0.22, 0.53)	5.7% (4.1-7.2) <sup>16</sup>	3248	3229
itt ior	l Heal nizatio	World Orgai					

[			Our						Sumr	nary of findin	gs		
		Quality assessment				No of patients Effect							
	No of studie s (Ref)	Desig n	Limitation s	Consistenc y	Directn ess	Other considerati ons	Active manage ment	Standard procedure s	Baseline Risk (95%Cl)	Relative risk (95%Cl)	NNT (95%CI)	Quality	Importanc e
	Benefits	:											
	Materna	l deaths					-						
	0	-	-	-	-	-	-	-	-	-	-	-	8.5
	Admissi	on to inten	sive care unit			-	-	-		-			
	0	-	-	-	-	-	-	-	-	-	-	-	6.4
	Blood lo	ss ≥ 500 m	l										
	4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> <sup>17</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 8.3% (6.3, 10.3) max 17.9% (15.3, 20.5)	0.38 (0.32, 0.46)	min 8 (6.7, 11.2) max 16 (11.7, 24.7)		6.3
ł	Blood lo	oss ≥ 1000 r	ml						1				
	4 PW 00 <sup>1</sup> Ad 97 Br 88 Du 90 Hi 98	RCT	serious limitation <sup>2,3,</sup> 17	no important inconsistenc y	some uncertai nty about directne ss <sup>4,5</sup>	none	3126	3158	min 1.5% (0.6-2.4) max 3.2% (2.0-4.4)	0.33 (0.21, 0.51)	min 41 (26.5, 90.1) max 73 (43.3, 225.5)		7.7
	Need for	· blood trar	sfusion					-					
	5 PW 00 <sup>1</sup> Ad 97 Br 93 Br 88	RCT	minor limitation <sup>3,8</sup>	no important inconsistenc y	some uncertai nty about directne ss <sup>7</sup>	none	3229	3248	5.7% (4.1-7.2) <sup>16</sup>	0.34 (0.22, 0.53)	28 (18.7, 59,1) <sup>16</sup>		7.8
	Du 90 Hi 98											<del>World</del> Orgai	<del>l Healt</del> h nizatior

### What would you recommend?

- Rate the importance of outcomes
- Check the quality of evidence
- Decide on your recommendation



### What would you recommend?

 Active management of third stage of labour should be offered by skilled attendants to all women. (Strong recommendation, moderate quality evidence)



# **Expertise needed for guideline development**

- Literature search and analysis
- Epidemiology and biostatistics
- Healthcare research
- Clinical expert knowledge
- Social group processes
- Writing and editing of texts
- Production of guideline products



### **Benefits and limitations of clinical guidelines**

- Improving quality of care
- Improving information about optimal care
- Summary of research findings
- External accountability
- Basis for teaching and education
- Basis for interdisciplinary cooperation
- Contributing to efficient care
- Setting health care priorities

- Cookbook medicine
- Unrealistic expectations
- Loss of clinical autonomy
- Professional resistance and concern for legal consequences
- Misuse by governmental authorities
- Uncertainty about costeffectiveness
- Hidden political motives

Grol et al 2005



## **Implementation and behaviour change**

Usually effective	Sometimes effective and sometimes not	Of little or no effect	Effectiveness unknown
Outreach visits	Audit and feedback	Educational materials	Financial stimuli
Decision support, reminders	Efforts of opinion leaders	Courses, conferences	Administrative or organisational interventions
Interactive education	Local consensus meetings		
Multifaceted interventions	Patient oriented interventions		
Mass media interventions			

Bero et al, 1998



### Summary

- Evidence is a tough taskmaster
- Systematic reviews and critical appraisal essential
- Content experts alone insufficient
- Transparent system required
- Judgements should be explicit
- To make it worth while, implementation and evaluation have to be integral to process





